Eli Lilly and Company NYQ · LLY
Price alert —
Sign in to get a one-time email the moment LLY crosses your price. Free accounts included.
Sign in / create a free accountEli Lilly and Company is a major pharmaceutical manufacturer that develops and sells a range of prescription medicines globally, with a particular focus on treatments for diabetes and other cardiometabolic conditions, among other therapeutic areas. The company markets well-known insulin products like Humalog and Humulin, along with other medications across the United States, Europe, China, Japan, and other international markets.
The stock recently closed at $1,152.54, down 2.48% for the day. Over the past year, shares have traded in a range between $850.51 and $1,249.45, meaning the current price sits in the upper portion of that band, though it has pulled back from the 52-week high. The technical positioning shows the stock is neutral relative to its recent 21-day average. The RSI(2) reading of 3.5 indicates extremely oversold conditions on a very short-term basis, suggesting the stock has experienced sharp selling pressure in the last couple of trading sessions.
Investors may want to monitor how the stock behaves following this recent decline, particularly whether it stabilizes near current levels or continues to experience volatility. The company's next earnings report is scheduled for August 5, 2026, which will provide updated financial results and business updates. Short-term price movements and any sector-wide developments in healthcare and pharmaceuticals could also influence trading activity in the coming sessions.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
above KC1 lower, +0.25 ATR from EMA21 — no notable pattern
- · Aligned with weak uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $524.39 (fair range $205–$524); today's price sits 132% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Goodwill 5% of assets (organic growth)
- ✓ Positive retained earnings
- ✓ Gross margin 83% (pricing power)
- ✓ Net margin 35%
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.65 (fragile)
- ⚠ Debt/equity 3.24 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~40% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
LLY is a $1.1 trillion company, priced at 42× last year's earnings, and it moves more calmly than the market (beta 0.5).
Options idea
See more →About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25,…